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Edited by Barry HalliwellAbstract Fatty acid synthase (FAS) expression is markedly
elevated in HER2-overexpressing breast cancer cells. In this
study, diosgenin, a plant-derived steroid, was found to be eﬀec-
tive in suppressing FAS expression in HER2-overexpressing
breast cancer cells. Diosgenin preferentially inhibited prolifera-
tion and induced apoptosis in HER2-overexpressing cancer cells.
Furthermore, diosgenin inhibited the phosphorylation of Akt and
mTOR, and enhanced phosphorylation of JNK. The use of phar-
macological inhibitors revealed that the modulation of Akt,
mTOR and JNK phosphorylation was required for diosgenin-in-
duced FAS suppression. Finally, we showed that diosgenin could
enhance paclitaxel-induced cytotoxicity in HER2-overexpress-
ing cancer cells. These results suggested that diosgenin has the
potential to advance as chemopreventive or chemotherapeutic
agent for cancers that overexpress HER2.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Fatty acid synthase (FAS, EC 2.3.1.85), which catalyzes the
reductive synthesis of palmitate from acetyl-CoA and malonyl-
CoA, plays a central role in the anabolic conversion of dietary
calories into storage form of energy in mammals [1]. Numer-
ous clinical and basic studies indicate that high levels of FAS
are present in varieties of human cancers and are associated
with poor prognosis [2]. It has been demonstrated that inhibi-
tion of FAS with synthetic inhibitors or siRNA is selectively
cytotoxic to human cancer cell and leads to a signiﬁcant
anti-tumor eﬀect in various cancer xenografts [3–5]. Further-
more, high levels of FAS have been found in various cancer
precursor lesions, such as colon, stomach, esophagus, oral cav-
ity, prostate and breast [6], suggesting that activation of fatty
acid synthesis is required for carcinogenesis. Collectively,
overxpression of FAS occurs in a wide variety of human
precancerous and cancerous lesions, suggesting that FAS is a
potential drug target for chemoprevention or chemotherapy.
HER2 has been shown to regulate FAS expression through
PI3K/Akt signal transduction pathways, revealing a molecular*Corresponding author. Address: Institute of Biochemistry and
Molecular Biology, College of Medicine, National Taiwan University,
Taipei 100, Taiwan. Fax: +886 2 2391 8944.
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doi:10.1016/j.febslet.2007.11.021connection between FAS and HER2 in human breast cancer
cells [7]. HER2 (alternatively known as neu or erbB2), a mem-
ber of the EGFR family of transmembrane receptor tyrosine
kinases, is overexpressed in about 30% of breast cancers [8].
HER2 overexpression has been shown to be correlated with
poor prognosis, enhanced metastatic potential, and increased
chemoresistance of human cancers [9]. Notably, inhibition of
FAS preferentially induced apoptosis of HER2-overexpressing
cancer cells [10] and delayed tumor progression in neu-N trans-
genic mice [11], suggesting that upregulation of FAS expression
might play a role in HER2-mediated cell survival and tumori-
genesis. Taken together, targeting FAS might be a novel ap-
proach to treat or prevent HER2-overexpressing breast cancer.
In recent years, there has been a global trend toward the use
of natural substances present in fruits, vegetables, and herbs as
antioxidants and anti-cancer agents. Chemically, plant steroids
of the spirosolane series such as solasodine and tomatidine oc-
cur in most plant tissues, where they are thought to play a pro-
tective role as detergents of certain insects. Previous studies
have shown that solasodine is eﬀective in the treatment of skin
cancer [12], and tomatidine may beneﬁt cancer chemotherapy
by inhibiting multi-drug resistance in human cancer cells
[13]. In addition, diosgenin, a member of steroidal sapogenin
found in several plants including Solanum and Dioscorea spe-
cies, has gained in importance recently. Diosgenin has been
shown to have not only favorable eﬀects on lipid metabolism
[14] but also anti-tumor eﬀects on cancer cells [15–18].
Although these data suggest that diosgenin possesses strong
anti-neoplastic activities, its eﬀect against HER2-overexpress-
ing cancer cells is seldom mentioned.
Based on the facts that FAS expression plays an important
role in the survival and tumorigenesis in HER2-overexpressing
breast cancer, and that plant steroids have favorable eﬀects on
both lipid metabolism and anti-cancer, it promotes us to inves-
tigate whether the plant steroids could diminish FAS expres-
sion in HER2-overexpressing breast cancer. Examining the
structurally related plant steroids revealed that diosgenin was
most eﬀective suppression of FAS expression in HER2-
overexpressing breast cancer cells. Diosgenin preferentially
inhibited proliferation and induced apoptosis in HER2-
overexpressing cancer cells. Furthermore, we showed that the
modulating Akt, mTOR and JNK phosphorylation was poten-
tially required for diosgenin-induced FAS suppression. Final-
ly, diosgenin could speciﬁcally sensitize paclitaxel-induced
cytotoxicity in HER2-overexpressing cancer cells. These results
indicate that diosgenin could down-regulate FAS expression
and induce apoptosis in HER2-overexpressing cancer cellsblished by Elsevier B.V. All rights reserved.
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and further suggest that diosgenin has therapeutic implications
in HER2-overexpressing cancer cells.2. Materials and methods
2.1. Chemicals
Diosgenin, solasodine, and tomatidine (Fig. 1A), LY294002,
PD98059, rapamycin, G418, C75, palmitic acid, fatty acid-free bovine
serum albumin (BSA), and MTT were purchased from Sigma Chemi-Diosgenin
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Fig. 1. Eﬀects of diosgenin, solasodine, and tomatidine on the FAS express
diosgenin, solasodine, and tomatidine. (B) AU565 cells were incubated with D
at 37  C for 24 h. Immunoblotting was used to measure protein levels of FA
continuous exposure to diﬀerent concentrations of diosgenin, solasodine, and
is expressed as a percentage of the vehicle-only control. Data are means of th
Immunoblotting was used to measures HER2, FAS and b-actin in 435.neo
column: 435.neo and 435.eb cells were treated with various concentrations of
assays. The number of viable cells after treatment is expressed as a percent
experiments. Bars represent the S.E. *P < 0.05.cal Co. (St. Louis, MO, USA). SP600125 and SB203580 were pur-
chased from Calbiochem (San Diego, CA, USA). Antibodies for
FAS were purchased from BD Biosciences (Los Angeles, CA). Anti-
bodies for Akt, mTOR, p44/42 MAPK, p38 MAPK, JNK1, phos-
pho-mTOR (Ser2448), phospho-Akt (Ser-473), phospho-p44/p42
MAPK (Thr202/Tyr204), phosphor-p38 MAPK (Thr180/Tyr182)
and phosphor-JNK (Thr183/Tyr185) were purchased from Cell Signal-
ing Technology (Beverly, MA). b-Actin antibody was from Abcam
Inc. (Cambridge, MA). Anti-mouse and anti-rabbit antibodies conju-
gated to horseradish peroxidase were obtained from Santa Cruz Bio-
technology Inc. (Santa Cruz, CA). All other reagents and chemicals
were purchased from Sigma and were of an analytical grade.C
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Fig. 1 (continued)
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HER2-overexpressing human cancer cell lines, AU565 (breast ade-
nocarcinoma) and cell lines with low HER2 expression, including
MCF-7 (breast adenocarcinoma), and HBL-100, which is derived from
a normal human breast tissue transformed by SV40 large T antigen,
were obtained from American Type Culture Collection (Manassas,
VA). All of the cells were grown in DMEM/F12 supplemented with
fetal calf serum (Hyclone Laboratories, Logan, UT) and 1% penicil-
lin–streptomycin. The 435.neo and 435.eB transfectants, which were
kindly provided by Dr. Mien-Chie Hung (The University of Texas,
M.D. Anderson Cancer Center, Houston, TX), were cultured as de-
scribed before [19]. These cells were grown at 37 C in a humidiﬁed
atmosphere of 5% CO2.
For culturing cells in the presence of palmitate-bovine serum albu-
min complex, palmitate (Sigma) was ﬁrst complexed to fatty acid-free
bovine serum albumin as described [20]. Brieﬂy, four volumes of a 4%
bovine serum albumin solution in 0.9% NaCl were added to 1 volume
of 5 mM palmitate in ethanol and incubated at 37 C for 1 h to obtain
a 1 mM stock solution of bovine serum albumin-complexed palmitate.
2.3. Western blot analysis
Cells (1.5 · 106) were seeded onto a 100-mm tissue culture dish con-
taining 10% FCS DMEM/F12 and cultured for 24 h. Then cells were
incubated in 1% FCS DMEM/F12 treating with various agents as indi-
cated in ﬁgure legends. After treatment, cells were placed on ice,
washed with cold PBS, and lysed in lysis buﬀer. Western Blot was done
as described previously [21]. The intensity of the bands was scanned
and quantiﬁed with NIH image software.
2.4. Cell proliferation assays and ﬂow cytometry
As described previously [21], the eﬀects of diosgenin solasodine,
tomatidine and taxol on cell proliferation were examined by MTT
method, and the cell cycle analysis of the sub-G1 peak detection of
the apoptotic eﬀect was determined by ﬂow cytometry using propidi-
um-iodide staining.
2.5. Statistical analysis
All values were expressed as means ± S.D. Each value is the mean of
at least three separate experiments in each group. Students t-test was
used for statistical comparison. *Indicates the values are signiﬁcantly
diﬀerent from the control. (*P < 0.05).3. Results
3.1. Eﬀects of diosgenin, solasodine, and tomatidine on the
expression of FAS in HER2-overexpressing breast cancer
cells
Diosgenin, solasodine, and tomatidine (Fig. 1A) are natu-
rally occurring plant steroids and have been shown to haveanti-neoplastic activities. To investigate the possible relation-
ship between the chemical structure and the biological activi-
ties, we determined their inhibitory activities on the protein
level of FAS in HER2-overexpressing breast cancer cell lines.
We treated separately the HER2-overexpressing human breast
cancer AU565 cells with 10 lM of these compounds at 37 C
for 24 h, and the levels of FAS protein was analyzed. As shown
in Fig. 1B, among the tested compounds, diosgenin was the
most eﬀective compound in suppressing FAS expression.
3.2. Diosgenin preferentially inhibits the proliferation of HER2-
overexpressing breast cancer cells
To assess the biological activity of diosgenin, solasodine,
and tomatidine in terms of cell proliferation, HBL-100,
MCF-7, and AU565 cells were treated with these plant steroids
at diﬀerent concentrations for 24 h. The growth inhibition of
the tested cell lines was in a dose-dependent manner but to var-
ious extents (Fig. 1C). AU565 cells that overexpress HER2
showed higher susceptibility to diosgenin than did HBL-100
or MCF-7 cells, resulting in lower cell viability. Both HBL-
100 and AU565 cells were sensitive to solasodine. Tomatidine,
in contrast, showed higher cytotoxicity against HBL-100 cells.
To avoid the genetic complexities associated with established
cancer cell lines, we compared the sensitivity of 435.neo cells,
which were established by transfecting the neomycin resistance
gene alone into MDA-MB-435 cells, with that of isogenic
HER2-transfected MDA-MB-435 (435.eb). Consistent with
our expectations, 435.eb cells were more sensitive to diosgenin
than were 435.neo cells (Fig. 1D). Overall, these results suggest
that diosgenin preferentially suppresses the growth of HER2-
overexpressing cancer cell lines.3.3. Diosgenin preferentially promotes apoptotic cell death in
HER2-overexpressing breast cancer cells
We next examined whether the loss of cell viability was due to
an increase in apoptotic cell death. The percentage of apoptotic
cells in the sub-G1peakof diosgenin-treated cells weremeasured
by ﬂow cytometry. As shown in Fig. 2, compared with vehicle-
treated control, diosgenin dramatically increased the amount
of apoptotic cells (sub-G1 cells) in the HER2-overexpressing
cancer cell lines. In contrast, in HER2 low-expressing cell lines,
the level of apoptotic cells was similar after either vehicle or dios-
genin treatment. In addition, we also found that diosgenin pref-
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Fig. 3. Exogenous palmitate suppresses diosgenin-induced cancer cell
cytotoxicity. (A) AU565 cells were exposed to vehicle (control) or to
diosgenin (12.5 lM), in the presence or absence of 75 lM palmitate.
After 24 h, cell viability was determined by MTT assays. Bars
represent the S.E. *P < 0.05. (B) AU565 cells were exposed to vehicle
(control) or to diosgenin (20 lM), in the presence or absence of 75 lM
palmitate. After 24 h, PARP cleavage was assessed by Western blot
analysis. (C) 435.eb cells viability was determined by MTT assays after
continuous exposure to diﬀerent concentrations of C75, a synthetic
FAS inhibitor, at 37 C for 24 h. The number of viable cells after
treatment is expressed as a percentage of the vehicle-only control.
Data are means of three independent experiments. Bars represent the
S.E.
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Fig. 2. Diosgenin induces apoptosis in HER2-overexpressing cancer
cell lines but not in HER2 low-expressing cancer cell lines. Cells were
treated with vehicle or diosgenin for 24 h (HBL-100, MCF-7 and
AU565) or 48 h (435.neo and 435.eb) then harvested and subjected to
sub-G1 DNA content analysis. The level of apoptosis induced by
vehicle was set at 1 and the level of apoptosis induced by diosgenin was
expressed relative to this value. Columns, average of three independent
experiments; Bars represent the S.E. *P < 0.05.
5738 C.-T. Chiang et al. / FEBS Letters 581 (2007) 5735–5742erentially induced apoptosis in 435.eb cells when compared with
435.neo cells (P < 0.05). Therefore, diosgenin can preferentially
induce apoptosis in HER2-overexpressing cancer cell lines.
3.4. Palmitate suppresses diosgenin-induced cytotoxicity in
HER2-overexpressing cancer cells
To conﬁrm that the cell cytotoxicity induced by diosgenin
was related to FAS inhibition, AU565 cells were exposed for
24 h to diosgenin in the presence of 75 lM palmitate. Palmi-
tate markedly reduced the cytotoxic eﬀect of diosgenin, as
the percentage of viable cells was signiﬁcantly decreased after
the addition of exogenous palmitate (Fig. 3A). Poly ADP-ri-
bose polymerase (PARP), cleaved by caspases during apopto-
sis to produce Mr 86000 fragments, was measured as a marker
of apoptosis by immunoblotting. Diosgenin induced corre-
sponding increases in the PARP cleavage, and addition of
exogenous palmitate reduced the cleavage (Fig. 3B). To test
whether that the suppression of FAS really critical for dios-
genins ability to inhibit proliferation in HER2-overexpressing
cancer cell lines, 435.eb cells were treated with C75, a synthetic
FAS inhibitors, at diﬀerent concentrations for 24 h (Fig. 3C).
The growth inhibition of the 435.eb cells was in a dose-depen-
dent manner. In contrast, the suppression of FAS mimicked
the diosgenins eﬀect.
3.5. Diosgenin downregulates phospho-Akt and phospho-mTOR,
and upregulates phospho-JNK levels in HER2-
overexpressing breast cancer cells
Akt, ERK, and JNK have been shown to be involved in
FAS regulation in various cell types [22–25]. To examine
whether the activities of Akt and MAPKs are aﬀected by dios-
genin, we analyzed the phosphorylation of Akt and MAPKs in
AU565 cells after treatment with diosgenin (5–20 lM) for 24 h.
Immunoblot analysis with anti-phospho-speciﬁc antibody was
then performed. As shown in Fig. 4A, diosgenin inhibited the
phosphorylation of Akt and its downstream mTOR. In con-
trast, diosgenin enhanced JNK phosphorylation. Diosgenin
did not aﬀect p38 and ERK phosphorylation.
3.6. Eﬀects of kinase inhibitors on the FAS expression in HER2-
overexpressing breast cancer cells
In further studies, we examined whether inhibition of FAS
expression in AU565 by diosgenin is mediated through modu-lation of Akt, mTOR, and JNK phosphorylation. As shown in
Fig. 4B, treating the cells with the inhibitors of PI3K
(LY294002) and mTOR (Rapamycin) signiﬁcantly reduced
FAS protein expression. Treatment with JNK inhibitor
SP600125 rendered diosgenin unable to suppress FAS expres-
sion and also inhibited diosgenins ability to induce apoptosis
(Fig. 4C). Taken together, it suggests that diosgenin inhibits
FAS expression by repressing the phosphorylation of Akt
and mTOR, and activating JNK phosphorylation in AU565
cells.
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Fig. 4. (A) Eﬀects of diosgenin on the Akt, mTOR and MAP kinases phosphorylation in HER2-overexpressing breast cancer cells. AU565 cells were
treated with the PI3K inhibitors LY294002 (LY; 25 lM) or MEK1 inhibitor PD98059 (PD; 50 lM) or diosgenin (5, 10 and 20 lM) at 37 C for 24 h.
Levels of phosphorylated Akt, mTOR, ERK1/2, p38 MAPK and JNK1/2 was analyzed by immunoblotting with phopho-Akt (Ser-473), phopho-
mTOR (Ser-2448), phopho-p44/42 MAPK (Thr202/Tyr204), phopho-p38 MAPK (Thr180/Tyr182) and phopho-JNK (Thr183/Tyr185) antibodies.
Immunoblotting with b-Actin antibody demonstrated equivalent protein in each lane. (B) AU565 cells were incubated with PI3K inhibitor LY294002
(25 lM), JNK inhibitor SP600125 (25 lM), and mTOR inhibitor rapamycin (100 nM) in the presence or absence of diosgenin (20 lM) at 37 C for
24 h. Cells were harvested and immunoblotting was used to measure levels of FAS protein and b-actin. (C) AU565 cells were incubated with JNK
inhibitor SP600125 (25 lM) in the presence or absence of diosgenin (20 lM) at 37 C for 24 h. Cells were harvested and PARP cleavage was assessed
by western blot analysis.
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overexpressing breast cancer cells
Previous studies have shown that HER2 overexpression can
confer resistance to chemotherapeutic agents in breast cancer
cells [26] and that inhibition of FAS can sensitize HER2-over-
expressing cancer cells to paclitaxel [27]. Because diosgenin can
inhibit FAS expression in HER2-overexpressing cancer cells,
we thus evaluated whether diosgenin could sensitize HER2-
overexpressing cancer cells to the chemotherapeutic agent pac-
litaxel.
To determine the eﬀect of diosgenin on paclitaxel-induced
cytotoxicity, we treated 435.eb and 435.neo cells with increas-
ing concentrations of paclitaxel (5–20 nM) in the absence or
presence of 20 lM diosgenin. After treatment for 48 h, cell via-
bility was measured using a MTT assay. As shown in Fig. 5A,
diosgenin could enhance paclitaxel-induced cytotoxicity in
435.eb cells, but not in 435.neo cells (Fig. 5B). Taken together,
the above data showed that diosgenin can speciﬁcally enhance
the cytotoxicity induced by paclitaxel in HER2-overexpressing
cancer cells but not in HER2 low expressing cancer cells.4. Discussion
The practice of dietary agents for treating the diseases is well
known from ancient times. Recently, some light has been
focused on steroid like compounds present in numbers of dietary
agents. In this study, we demonstrated that among the tested
naturally occurring steroids, diosgenin showed the most eﬀective
inhibition of FAS expression in HER2-overexpressing cancer
cells. Further analysis indicated that diosgenin preferentially
inhibited the proliferation of HER2-overexpressing cancer cells.
In addition, diosgenin could speciﬁcally sensitize HER2-over-
expressing cancer cells to paclitaxel-induced cytotoxicity. Inter-
estingly, both diosgenin and solasodine were eﬀective inhibition
of proliferation in AU565 cells, while tomatidine was not, sug-
gesting the presence or absence of the unsaturation at D5 may
lead to major modiﬁcations in biological activity in HER2-
overexpressing cells. These results will provide new information
for the study of these functional groups in the future.
It has been hypothesized that increased exposure to exoge-
nous estrogens from dietary phytoestrogens may reduce breast
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Fig. 5. Diosgenin enhances paclitaxel-induced growth inhibition in
HER2-overexpressing cancer cells. 435.eb (A) and 435.neo (B) cells
were treated for 48 h with either vehicle or 20 lM diosgenin in
combination with the indicated concentrations of paclitaxel. Loss of
cell viability was measured using the MTT assay.
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lignans, and sterols. Genistein, for example, has been shown to
inhibit the growth of a wide range of both hormone-dependent
and hormone-independent cancer cells [29]. Diosgenin, an
important compound in the pharmaceutical industry as a
natural source of steroidal hormones, has gained attention
recently. Studies suggest that it can be absorbed through gut
[14] and has anti-tumor activities. The anti-tumor eﬀects of
diosgenin have been demonstrated to be mediated through dis-
ruption of Ca2t homeostasis [15], inhibition of NF-jB [18,30],
activation of p53, and modulation of caspase-3 activity [30,31].
We demonstrated here for the ﬁrst time that fatty acid synthe-
sis is required for diosgenin-induced cytotoxicity in HER2-
overexpressing cancer cells (Fig. 3). It has been well-docu-
mented that HER2-overexpressing cancer cells overexpress
FAS and thus are sensitive to treatments that target FAS
[10]. The concept of oncogene addiction suggests that cancer
cells are often physiologically dependent on the continued
activity of speciﬁc activated or overexpressed oncogenes for
maintenance of their malignant phenotype, which providesan Achilles heel for tumors that can be exploited in cancer
therapy [32]. Because FAS is overexpressed in HER2-over-
expressing cancer cells, it is reasonable to assume that dios-
genin can suppress the survival of HER2-overexpressing
cancer cells.
Activation of Akt signalings have been demonstrated to
upregulate the expression of FAS in various cell types, includ-
ing breast [24], prostate [23], and ovarian cancer cells [33]. In
this study, the phosphorylation of Akt was suppressed dios-
genin in AU565 cells that overexpress HER2 (Fig. 4A). Fur-
thermore, the expression of FAS was also inhibited by the
PI3K inhibitor LY294002 (Fig. 4B). HER2 has been shown
to regulate FAS expression through Akt-dependent mecha-
nism [7]. Given that Akt can be either activated by PI3K or
negatively regulated by PTEN [34], investigations into the pos-
sible involvement of PI3K or PTEN in diosgenin-induced
down-regulation of Akt are currently in progress.
It is noteworthy that our results illustrate that mTOR signal-
ing plays an important role in the upregulation of FAS in
HER2-overexpressing cancer cells (Fig. 4), which is consistent
with the a recent report by Yoon et al. [35]. There is a clear
association between mTOR activation and HER2 overexpres-
sion in breast cancer [36] and activation of this signaling path-
way has been associated with poorer prognosis. Many reports
have suggested that the mTOR pathway plays an important
role in the susceptibilities of chemopreventive or chemothera-
peutic agents to kill cancer cells [21,37]. In accordance with this
concept, diosgenin could sensitize paclitaxel-induced cytotox-
icity in HER2-overexpressing cancer cells (Fig. 5).
The c-Jun N-terminal kinase (JNK) pathway represents one
sub-group of MAP kinases that is activated by cytokines and
exposure to environmental stress [38]. JNK has been reported
to have a role in the induction of apoptosis, but have also
been implicated in enhancing cell survival and proliferation
[39]. Interestingly, tamoxifen-induced apoptosis was found
to be related to the activation of the JNK phosphorylation
and increased caspase 3 activity [40], supporting a role for
JNK in facilitating tamoxifen-induced apoptosis. Our results
here suggest that JNK may play a role in diosgenin-induced
FAS suppression and apoptosis (Fig. 4B and data not
shown). In contrast, suppressing FAS expression by inhibit-
ing JNK signaling has also been demonstrated by our and
other laboratories [22,41]. Taken together, alterations of
JNK activity may lead to changes of FAS levels and cell
survival. The role of JNK in the regulation of FAS expres-
sion and apoptosis is still controversial and merits further
investigation.
In conclusion, elevated FAS expression is associated with
HER2 overexpression, which is regarded as a poor prognostic
marker in breast cancer cells. We provide experimental evi-
dence here for the ﬁrst time to demonstrate that diosgenin
could suppress FAS expression and modulate Akt, mTOR
and JNK phosphorylation in HER2-overexpressing cancer
cells. These results highlight the potential of use diosgenin as
a unique chemotherapeutic modulator in the prevention or
treatment of HER2-overexpressing cancer.Acknowledgements: The authors would like to thank Prof. Mien-Chie
Hung for generous providing cancer cell lines 435.neo and 435.eB. This
study was supported by the National Science Council NSC 95-2320-B-
002-111 and NSC95-2321-B-002-016.
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